pH‐Responsive Hexa‐Histidine Metal Assembly (HmA) with Enhanced Biocatalytic Cascades as the Vehicle for Glucose‐Mediated Long‐Acting Insulin Delivery
Source abstract
Abstract
Abstract Diabetes has been listed as one of the three major diseases that endanger human health. Accurately injecting insulin (Ins) depending on the level of blood glucose (LBG) is the standard treatment, especially controlling LBG in the long‐term by a single injection. Herein, the pH‐responsive hexa‐histidine metal assembly (HmA) encapsulated with enzymes (GOx and CAT) and Ins (HmA@GCI) is engineered as the vehicle for glucose‐mediated insulin delivery. HmA not only shows high proteins loading efficiency, but also well retained proteins activity and protect proteins from protease damage. Within HmA, the biocatalytic activities of enzymes and the efficiency of the cascade reaction between GOx and CAT are enhanced, leading to a super response to the change of LBG with insulin release and efficient clearance of harmful byproducts of GOx (H2O2). In the treatment of diabetic mice, HmA@GCI reduces LBG to normal in half an hour and maintains for more than 5 days by a single subcutaneous injection, and nearly 24 days with four consecutive injections. During the test period, no symptoms of hypoglycemia and toxicity to tissues and organs are observed. These results indicate that HmA@GCI is a safe and long‐acting hypoglycemic agent with prospective clinical application.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Graphene and Nanomaterials Applications · Pancreatic function and diabetes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Ophthalmology and Optometry Eye Hospital School of Biomedical Engineering Wenzhou Medical University Wenzhou 325035 China
Wenzhou Institute Wenzhou Key Laboratory of Perioperative Medicine University of Chinese Academy of Sciences Wenzhou 325001 China
Department of Ophthalmology Huzhou Central Hospital Affiliated Central hospital Huzhou University Huzhou 313000 China
Wenzhou Celecare Medical Instruments Co., Ltd Wenzhou 325000 China
References (45)
Show source-provided references
1. Tripathi B. K. · Med. Sci. Monit. · 2006 · 12
2. 10.1016/j.diabres.2021.10911910.1016/j.diabres.2021.109119 ↗
3. 10.1016/S0140-6736(12)61031-910.1016/S0140-6736(12)61031-9 ↗
4. 10.1016/j.cmet.2021.03.01410.1016/j.cmet.2021.03.014 ↗
5. 10.1016/j.jconrel.2008.08.00910.1016/j.jconrel.2008.08.009 ↗
6. 10.1111/j.1464-5491.2012.03605.x10.1111/j.1464-5491.2012.03605.x ↗
7. 10.1056/NEJM19930610328230610.1056/NEJM199306103282306 ↗
8. Grp D. R. · Z. Kinderheilkd. · 1994 · 125 · 177
9. 10.1007/s00125-020-05192-710.1007/s00125-020-05192-7 ↗
10. 10.1016/j.jconrel.2017.09.00310.1016/j.jconrel.2017.09.003 ↗
11. 10.1016/j.mayocp.2016.06.01010.1016/j.mayocp.2016.06.010 ↗
12. 10.1038/nchem.285710.1038/nchem.2857 ↗
13. 10.1038/s41551-019-0508-y10.1038/s41551-019-0508-y ↗
14. 10.1021/nn400630x10.1021/nn400630x ↗
15. 10.1016/j.actbio.2017.01.01610.1016/j.actbio.2017.01.016 ↗
16. 10.1016/j.jconrel.2020.01.03810.1016/j.jconrel.2020.01.038 ↗
17. 10.1021/acsnano.9b0639510.1021/acsnano.9b06395 ↗
18. 10.1016/j.carbpol.2013.12.06710.1016/j.carbpol.2013.12.067 ↗
19. 10.1016/j.jconrel.2017.01.04310.1016/j.jconrel.2017.01.043 ↗
20. 10.1126/science.50500510.1126/science.505005 ↗
21. 10.1126/sciadv.aaw435710.1126/sciadv.aaw4357 ↗
22. 10.1073/pnas.142468411210.1073/pnas.1424684112 ↗
23. 10.1126/sciadv.aaq072310.1126/sciadv.aaq0723 ↗
24. 10.1021/bm034541310.1021/bm0345413 ↗
25. 10.1039/C8CC02708K10.1039/C8CC02708K ↗
26. 10.1016/j.biomaterials.2020.12045810.1016/j.biomaterials.2020.120458 ↗
27. 10.1021/acsami.1c0194310.1021/acsami.1c01943 ↗
28. 10.1039/C9NR01554J10.1039/C9NR01554J ↗
29. 10.1073/pnas.150540511210.1073/pnas.1505405112 ↗
30. 10.1021/acsnano.6b0689210.1021/acsnano.6b06892 ↗
31. 10.1021/acs.nanolett.6b0384810.1021/acs.nanolett.6b03848 ↗
32. 10.1016/j.ijbiomac.2020.05.09710.1016/j.ijbiomac.2020.05.097 ↗
33. 10.1002/admi.20200063210.1002/admi.202000632 ↗
34. 10.1007/s12274-022-4105-010.1007/s12274-022-4105-0 ↗
35. 10.1002/marc.20120041110.1002/marc.201200411 ↗
36. 10.1039/D2BM00280A10.1039/D2BM00280A ↗
37. 10.1016/j.actbio.2019.03.05810.1016/j.actbio.2019.03.058 ↗
38. 10.1021/acs.molpharmaceut.0c0021210.1021/acs.molpharmaceut.0c00212 ↗
39. 10.1016/j.actbio.2021.05.00110.1016/j.actbio.2021.05.001 ↗
40. 10.1039/D1BM00063B10.1039/D1BM00063B ↗
41. 10.2147/IJN.S13298410.2147/IJN.S132984 ↗
42. 10.1021/acs.biomac.5b0102010.1021/acs.biomac.5b01020 ↗
43. 10.1016/j.actbio.2022.09.02910.1016/j.actbio.2022.09.029 ↗
44. 10.1023/B:BILE.0000045650.90384.b210.1023/B:BILE.0000045650.90384.b2 ↗
45. 10.1007/978-1-4939-2425-7_2310.1007/978-1-4939-2425-7_23 ↗